Mar. 4 at 12:11 PM
$PSNL From TD Cowen Conference yesterday.
Tyler Van Buren asked Moderna's CFO:
"Possible pivotal readout for adjuvant melanoma in 2026. If this hits, could transform the entire company... What do you think is the probability that it comes in 2026 versus 2027?"
Jamey Mock replied: "I can't give a probability. It's OBVIOUSLY ENOUGH that we said it could come in 2026."
Moderna wouldn't publicly guide to a 2026 readout possibility unless they had reasonable confidence.
The Phase 3 readout could come in 2026. Moderna is already scaling manufacturing for commercial launch. And the 5-year data showing a sustained 49% risk reduction makes a positive Phase 3 readout more probable than ever.
And here's what nobody at TD Cowen was talking about.
Before Moderna can manufacture a personalized cancer vaccine for any patient, they need that patient's tumor sequenced first by Personalis.
PSNL might be the picks and shovels play on the most important cancer treatment breakthrough in a generation
